News

Alcyomics Skimune® the cost effective alternative to the animal model for assessing the safety, toxicity & efficacy in cellular therapies.

March 26, 2024

Cellular therapies embarked on their journey in the 1950s, marked by the groundbreaking initiation of haematopoietic stem cell transplantation for leukaemia. In these pioneering studies, cells harvested from a patient’s own bone marrow (autologous transplants) acted as a lifeline, rescuing the patient post-chemotherapy or radiotherapy. The primary objective was to eliminate residual leukaemia, paving the way for healthy bone marrow cells to repopulate the haematopoietic system.

Allogenic transplants, rely on human leukocyte antigen (HLA) matched bone marrow, peripheral blood, or cord blood to combat residual disease by leveraging the incoming T and natural killer (NK) cells. This strategy instigates Graft versus Leukaemia (GvL) or Graft versus Tumour (GvT) effects. However, graft versus host disease (GvHD) poses a significant challenge, wherein incoming T cells may inadvertently target the skin, gut, and liver.

Alcyomics stands at the forefront of this early legacy, owing to over three decades of research in predicting GvHD led by Emeritus Professor Anne Dickinson, who’s work culminated in Skimune®, a revolutionary human skin explant test designed to accurately anticipate adverse immune reactions. The Skimune® platform not only showcases the specificity of T-cell clones crucial for leukaemia treatment (Nature Medicine in 2002) but also provides key data for other therapy types including: small, large molecules, nanomedicines, and gene therapies.

These pioneering early cellular therapies have paved the path for chimeric antigen receptor (CAR-T) advanced therapies. These new therapies represent an innovative and promising approach in cancer treatment. It involves harnessing a patient’s own immune cells, specifically T cells, and modifying them to better recognize and attack cancer cells. Despite the progress, concerns linger regarding response specificity, bystander effects, and GvHD onset, particularly with the emergence of allogenic CAR-T therapies.

Once again, Alcyomics’ Skimune assays emerge as indispensable tools for assessing adverse immune reactions to CAR-T cell therapy. As an established CRO, Alcyomics boasts unique, human-based technology platforms that provide a robust, human alternative to animal testing. The Skimune® technology, promotes enhanced predictive capabilities compared to conventional methods, spans a wide array of treatment modalities, including cellular therapy products, by anticipating adverse graft-versus-host reactions.

Related Posts

Get in touch

How can we assist?